Events supposedly attributable to vaccination or immunization of COVID-19 vaccines in Brazil: a cross-sectional study

Deleted Journal, Journal Year: 2025, Volume and Issue: 22(1)

Published: Jan. 2, 2025

Abstract COVID-19 vaccines effectively reduce morbidity and mortality but are associated with Events Supposedly Attributable to Vaccination or Immunization (ESAVI). This cross-sectional study examined the incidence characteristics of ESAVI in Brazil during 2021, using data from e-SUS Notifica Vacivida. Among 109,424 reports, rates were 30.82 83.08 symptoms per 100,000 doses. Most reports involved women (70.83%), individuals aged 30–39, residents southern region. Common included headache, fever, myalgia. AstraZeneca accounted for 56.79% cases. Non-severe cases predominated (95.03%), 78.7% classified as “product-related according literature.” Mortality was rare (0.03%), a significant association identified between DNA deaths (χ 2 = 4.333; p 0.037; OR 2.673; 95% CI 1.020–7.007). Regional disparities evident, higher incidences South Southeast. Underreporting non-severe remains challenge. Logistic regression showed lower odds severe among adults Black/Brown individuals, while Pfizer initial doses linked odds. These results highlight safety emphasizing need strengthened post-vaccination surveillance address regional disparities, health inequities, vaccine hesitancy.

Language: Английский

Use of mobile technology for reporting the pharmacovigilance of vaccines in Panama

Preventive Medicine Reports, Journal Year: 2025, Volume and Issue: unknown, P. 103056 - 103056

Published: March 1, 2025

Monitoring adverse reactions is essential to confirm vaccine safety profiles. Studies using electronic tools for data collection may reach a broader audience, improving efficiency and integrity, reducing study costs simplifying compared with nonelectronic methods. This aimed validate versus paper diaries reporting postimmunization in Panama. An experimental design was conducted three groups (children, pregnant women, older adults). Groups were divided into one subgroup diary diary. Diary assignments subsequently reversed children group, which parents completed. Symptoms frequency collected 2020 2021. Information reported entered an case report form reconciled. Users' adherence, differences between symptom users' acceptability of evaluated. A total 180 participants included: 79 children, 21 80 adults. Children group showed greater adherence both diaries. No significant found response times the groups. More symptoms The experience diaries, no matter one, similar. Results indicate young people adapt better technological than adults, suggesting should be adjusted according user's age. Furthermore, applications offer suitable pharmacovigilance alternatives, providing real-time information, requiring fewer staff, leading improved health outcomes, patient compliance, research public analysis, supporting global development.

Language: Английский

The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(11), P. 1366 - 1366

Published: Oct. 25, 2024

The COVID-19 pandemic has significantly accelerated progress in RNA-based therapeutics, particularly through the successful development and global rollout of mRNA vaccines. This review delves into transformative impact on RNA with a strong focus lipid nanoparticles (LNPs) as pivotal delivery platform. LNPs have proven to be critical enhancing stability, bioavailability, targeted mRNA, facilitating unprecedented success vaccines like those developed by Pfizer-BioNTech Moderna. Beyond vaccines, LNP technology is being explored for broader therapeutic applications, including treatments cancer, rare genetic disorders, infectious diseases. also discusses emerging systems, such polymeric viral vectors, which offer alternative strategies overcome existing challenges related immune responses, tissue-specific targeting. Additionally, we examine pandemic's influence regulatory processes, fast-tracked approvals therapies, surge research funding that spurred further innovation field. Public acceptance grown, laying groundwork future developments personalized medicine. By providing an in-depth analysis these advancements, this highlights long-term evolution therapeutics precision drug technologies.

Language: Английский